Huang Lan
Known title: Chief Executive OfficerCIK: 0001731317
Associated companies
Transaction History
| BYSI | ▼ Sell | Gift | 260,582 | $0 | 3/20/2026 | View on chart |
| BYSI | ▼ Sell | Gift | 260,582 | $0 | 3/20/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
BYSI Discusses FDA Fast Track Designation for Plinabulin
BeyondSpring reported that the FDA has granted Fast Track designation to its drug Plinabulin for use after immune checkpoint inhibitor therapy in non‑squamous non‑small cell lung cancer. The company also mentioned a strategic transaction related to the program. The announcement appears alongside recent pre‑market and after‑hours activity that highlighted BYSI among active health‑care stocks.
BYSI Discusses FDA Fast Track Designation for Plinabulin. BeyondSpring reported that the FDA has granted Fast Track designation to its drug Plinabulin for use after immune checkpoint inhibitor therapy in non‑squamous non‑small cell lung cancer. The company also mentioned a strategic transaction related to the program. The announcement appears alongside recent pre‑market and after‑hours activity that highlighted BYSI among active health‑care stocks.